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ABSTRACT
Objectives: Recent studies using next-generation sequenc-
ing (NGS) analysis disclosed the importance of the intrinsic
activation of the B-cell receptor (BCR) pathway in the
pathogenesis of sporadic Burkitt lymphoma (sBL) due to
mutations of TCF3/ID3 genes. Since no definitive data are
available on the genetic landscape of endemic Burkitt
(eBL), we first assessed the mutation frequency of TCF3/
ID3 in eBL compared with sBL and subsequently the som-
atic hypermutation status of the BCR to answer whether an
extrinsic activation of BCR signaling could also be demon-
strated in Burkitt lymphoma.
Methods:We assessed the mutations of TCF3/ID3 by
RNAseq and the BCR status by NGS analysis of the immuno-
globulin genes (IGs).
Results:We detected mutations of TCF3/ID3 in about 30%
of the eBL cases. This rate is significantly lower than that
detected in sBL (64%). The NGS analysis of IGs revealed
intraclonal diversity, suggesting an active targeted somatic
hypermutation process in eBL compared with sBL.
Conclusions: These findings support the view that the anti-
genic pressure plays a key role in the pathogenetic pathways
of eBL, which may be partially distinct from those driving
sBL development.
The B-cell receptor (BCR) is essential for normal
B-cell development and maturation. There is increasing evi-
dence that BCR signaling is implicated in B-cell malignan-
cies. A role for BCR signaling in lymphoma has been
inferred by studying immunoglobulin genes in human
lymphomas and engineering mouse models.1 Among the
different types of B-cell malignancies, several different tac-
tics are applied for activation of the BCR signaling.2
Although they convey on the same pathway, understanding
where the signaling is modulated may help unravel which
B-cell malignancies would likely respond to which kind of
targeted therapies.
Roles for antigen-dependent and antigen-independent
BCR signaling have now been described for several differ-
ent lymphoma types.2 Evidence for a causal relationship be-
tween hepatitis C virus infection and lymphomagenesis has
been found in a subset of splenic marginal zone lymph-
omas.3 Chronic exposure to microbial antigens has been
implicated in the pathogenesis of other types of marginal
zone lymphomas, such as Helicobacter pylori in mucosa-
associated lymphoid tissue lymphoma and Chlamydia psit-
taci in ocular adnexa lymphoma.4-6 An increasing number
of antigens bound to the BCR on chronic lymphocytic leu-
kemia cells have been identified, including autoantigens ex-
pressed on dying cells, as well as viral, bacterial, and fungal
antigens.7
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On the other hand, in diffuse large B-cell lymphoma
(DLBCL) and Burkitt lymphoma (BL), next-generation
sequencing (NGS) studies have revealed recurrent muta-
tions of genes belonging to the BCR pathway, converging in
the two different types of intrinsically deregulated down-
stream BCR signals—namely, chronic active signaling in
DLBCL and tonic signaling in BL.8,9
In DLBCL, mutations affecting the BCR pathway are par-
ticularly enriched in cases showing the activated B-cell–like
(ABC) molecular phenotype. In particular, mutations of
CD79B and CARD11 have been identified in about 10% of
ABC DLBCL cases. These mutations are sufficient to intrin-
sically activate survival signaling in the malignant B cells and
obviate the need for upstream BCR signaling.8 Most of spor-
adic Burkitt lymphomas (sBLs) (70%) harbor gain-of-func-
tion mutations affecting the TCF3 gene or mutations
disrupting the TCF3-negative regulator ID3.9-11 The overall
consequence of ID3 and TCF3 mutants in BL is an impairment
of TCF3/ID3 inhibitory heterodimerization that results in an
increasing expression of BCR genes and activation of a tonic
form of BCR signaling, which is antigen independent.9-11
Taking into consideration that no definitive data are avail-
able on the genetic landscape of endemic BL (eBL),10,12 as
well as the different environment in which eBL emerges, char-
acterized by an uninterrupted presence of malaria parasites, a
never-ending chronic antigenic stimulation, splenomegaly, and
concurrent infections by viruses, bacteria, and parasites,12 in
the present study we aim to better understand the BCR activa-
tion pathway in eBL compared with sBL. To this end, we first
analyzed the frequency of the TCF3 or its negative regulator
ID3 gene mutations by RNAseq and Sanger sequencing and
subsequently looked for a possible association with somatic
hypermutation status (SHM) of BCR by NGS analysis and
Sanger sequencing of immunoglobulin genes as indicative of
an active ongoing interaction with antigens.
Materials and Methods
Patients
A total of 37 BL samples preserved in RNA later (RNA
stabilization Reagent; Qiagen, Valencia, CA) were collected
from the Department of Human Pathology of the Lacor
Hospital, Uganda; from the Department of Medical
Biotechnologies, University of Siena, Italy; and from “L.A
Seragnoli” Haematopathology Unit, Policlinico S. Orsola,
Bologna, Italy. Formalin-fixed, paraffin-embedded samples
were available for all. Overall, 26 BL samples were col-
lected from endemic areas in Uganda, Africa (eBL), while
the other 11 BL cases were collected in Italy (sBL). Clinical
epidemiologic details of the 37 BL cases are summarized in
Table 1 .
All cases were previously analyzed by gene expression
profile (GEP) analysis and showed a signature consistent
with molecular BL.13,14
Total RNA was extracted from BL samples with Trizol,
according to manufacturer’s procedure (Invitrogen, Life
Technologies, Carlsbad, CA). The study was approved by
each institutional ethical committee, and written permission
and informed consent have been obtained before sample
collection in accordance with the Declaration of Helsinki.
TCF3 and ID3Mutation Assessment by RNAseq
The paired-end libraries (2 75 base pairs [bp]) were pre-
pared according to the TruSeq RNA sample preparation v2
protocol (Illumina, San Diego, CA). The resulting libraries
were sequenced on a HiScan SQ (Illumina) following the
manufacturer’s instructions. Briefly, 2 lg Poly(A)þ RNA was
Table 1
Clinical-Epidemiologic Characteristics of Burkitt Lymphoma
Cases
Case No. Site Age, y Sex EBV
eBL78 Abdomen 6 M þ
eBL48 Jaw 10 M þ
eBL43 Gum 5 M þ
eBL15 Lymph node 9 F þ
eBL32 Jaw 7 months M þ
eBL35 Jaw 7 M þ
eBL36 Abdomen 4 M þ
eBL84 Jaw 9 F þ
eBL52 Jaw 7 M þ
eBL22 Jaw 6 M þ
eBL49 Jaw 7 M þ
eBL34 Jaw 10 F þ
eBL51 Jaw 9 M þ
eBL23 Jaw 7 M þ
eBL19 Abdomen 4 M þ
eBL40 Jaw 7 M þ
eBL63 Abdomen 7 F þ
eBL80 Gum 7 M þ
eBL74 Abdomen 5 M þ
eBL28 Gum 10 M þ
eBL50 Abdomen 8 F þ
eBL69 Jaw 8 F þ
eBL31 Palate 7 M þ
eBL20 Jaw 7 M þ
eBL57 Palate 10 F þ
eBL62 Jaw 9 M þ
sBL4169 Lymph node 39 M –
sBLE9 Abdomen 21 M –
sBL4452 Lymph node 46 M –
sBLE4 Abdomen 53 M –
sBL4324 Abdomen 52 F –
sBLE2 Lymph node 31 F –
sBLE3 Lymph node 43 F –
sBLE5 Abdomen 40 M –
sBL2552 Abdomen 28 M þ
sBL8274 Abdomen 23 F –
sBLE8 Abdomen 33 M –
eBL, endemic Burkitt lymphoma; sBL, sporadic Burkitt lymphoma; þ, positive; –,
negative.
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purified from total RNA using poly-T oligo–attached magnetic
beads and then used for fragmentation into 130- to 290-bp
fragments. The first strand of complementary DNA (cDNA)
synthesis was performed using reverse transcriptase enzyme
(SuperScript II; Invitrogen, Life Technologies) and random
hexamer primer, followed by generation of double-stranded
cDNA. AmpureXP beads (Beckman Coulter, Brea, CA) were
used to purify the cDNA, and an end-repair step was per-
formed to convert the overhangs, resulting from fragmentation,
into blunt ends by 30 to 50 exonuclease activity. A single
“A” nucleotide was added to the 30 ends of the blunt fragments
to prevent them from ligating to one another during the
adapter ligation reaction. This approach was adopted to ensure
a low rate of chimera (concatenated template) formation.
Subsequently, sequencing adapters were added to the ends of
the double-stranded (ds)–cDNA fragment, and a polymerase
chain reaction (PCR) reaction was used to selectively enrich
those ds-cDNA fragments that had adapter molecules on both
ends, amplifying the amount of ds-cDNA in the final libraries.
Last, PCR libraries products were purified by AmpureXP
beads, and quality control analysis was assessed using a DNA-
1000 (Agilent, Waldbronn, Germany). The quantification was
performed by the Quant-it PicoGreen dsDNA Assay Kit ac-
cording to the manufacturer’s protocol (Invitrogen, Life
Technologies). Sequence variants were obtained using the
SAVI (Statistical Algorithm for Variant Identification) algo-
rithm independently for each sample. Candidate somatic muta-
tions were obtained by eliminating common germline variants
and recurrence. Sanger sequencing was used for validation and
confirmation of TCF3 and ID3 single-nucleotide variants in
sBL.9-11,15,16
PCR Amplification and High-Throughput Sequencing
by Roche 454 GS Junior Instrument
In total, 1 mg total extracted RNA per case was transcribed
into cDNA using the QuantiTect Reverse Transcription Kit
Table 2
Modified FR1 BIOMED-2 Primersa
NGS, next-generation sequencing.
aForward and reverse primers are in blue, key sequences are in orange and yellow, and Multiplex Identifier (MID) sequences in green.
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(Qiagen) according to the manufacturer’s instructions.
Resulting cDNA was subjected to PCR amplification of the
IGVH locus by using modified BIOMED-2 framework region
1 (FR1) consensus primers in conjunction with a consensus J
segment primer.17
In this assay, each of the seven BIOMED-2 primers at
the 50 end contained an additional sequence, Multiplex
Identifiers, that barcodes the sample Table 2 . Thermal
cycling was performed on an Applied Biosystems 2720
Thermal Cycler using the BIOMED-2 protocols. Small
DNA fragments were removed using the AMPure PCR
purification system (Agencourt, Beverly, MA) following
the manufacturer’s protocol (http://454.com/downloads/
my454/documentation/gs-junior/method-manuals/454SeqSys_
AmpliconLibraryPrepMethodManual_Jun2013.pdf). Amplicons
were subsequently quantified using the Quant-iT PicoGreen
dsDNA reagent (Invitrogen Corporation, Life Technologies).
All amplicons were then pooled at an equimolar ratio.
Subsequently, the sample pool was diluted to a final concen-
tration of 1 107 PCR fragment molecules/lL.
The amplicon-PCR–derived fragments were annealed
to carrier beads and clonally amplified by emulsion PCR
(emPCR). The emPCR was performed according to the
manufacturer’s protocol (http://454.com/downloads/my454/
documentation/gs-junior/method-manuals/GSJunioremPCR
AmplificationMethodManualLib-A_March2012.pdf). The
beads were isolated and compartmentalized into droplets of
an aqueous PCR buffer in oil emulsion. Subsequently, the
emulsions were broken by isopropanol to facilitate collec-
tion of the amplified fragments bound to their specific
beads. The beads carrying single-stranded DNA templates
were enriched, counted, and deposited into the picotiter
plate for sequencing (http://454.com/downloads/my454/
documentation/gs-junior/method-manuals/GSJuniorSequen
cingManual_Jan2013.pdf).
Data analysis was performed using the Roche (Basel,
Switzerland) proprietary software package for the GS Junior
system. Image acquisition, image processing, and signal
processing were performed during the run.
An unmutated chronic lymphocytic leukemia (CLL)
case, BL cell lines, and reactive lymph node sequencing
were applied as control samples for monoclonality and
polyclonality.
Bioinformatical Analysis
By using the GS Junior system, we obtained, for each
sample, an average depth of 3,700 reads with a minimum
depth of 772 reads and a maximum depth of 7,869 reads.
The pooled raw sequences obtained by GS Junior
sequencing were split by using the 454 seqTool script and
custom script in Perl language according to different sam-
ple-specific tag sequences.
To reduce the single-nucleotide variant complexity,
each single subset of sequences was clustered by cap3 soft-
ware (http://bioweb.pasteur.fr/seqanal/interfaces/cap3.html)
with more than 98% overlap identity by obtaining a list of
consensus sequencing, and therefore the sequencing reads
that differed by up to two single-nucleotide substitutions or
gaps were aggregated.18 By using these stringent criteria,
artifactual clonotypes were minimized. For each consensus
sequence corresponding to different intrasample clones, we
calculated the number of raw sequences used to indicate the
abundance of each different rearrangement present in the sam-
ple. Finally, the consensus sequencing was multialigned by
the Clustalw (http://www.ebi.ac.uk/tools/clustalw2) program
with default parameters.19
Characteristic 454 sequencing errors, such as inser-
tions/deletions near homopolymer tracts, were also identi-
fied, and sequences containing such errors were also
discarded. Low-frequency clonotypes that differed by up to
1% from another clonotype with significantly higher fre-
quency were deemed to be the result of technical artifact
(PCR or sequencing artifacts), and the sequence differences
were corrected for clonotype aggregation.
Validation of NGS Data by Sanger Sequencing and
Subcloning
To validate the reliability of NGS data, 26 eBL and 11
sBL samples were amplified in two separated reactions.
Both reactions were carried using the FR1 VH-JH
BIOMED-2 primers as previously described.15
Purified PCR amplicons were subjected to direct sequenc-
ing and cloning into the pCRII-TOPO vector (TOPO TA
Cloning Kit; Invitrogen, Paisley, UK) and were used to trans-
form TOP 10 cells (Invitrogen) according to the manufac-
turer’s instructions. At least 20 clones per case were sequenced
in both directions with an ABI PRISM 310 Genetic Analyzer
(Applied Biosystems, Weiterstadt, Germany) using Sp6 re-
verse and T7 forward primers, respectively.
The sequences obtained from direct sequencing and
cloning were analyzed with the IMGT/V-QUEST (http://
www.imgt.org/IMGT_vquest/vquest?livret¼0&Option¼hu
manIg; Marie-Paule Lefranc [Marie-Paule.Lefranc@igh.
cnrs.fr], Universite´ de Montpellier, CNRS, LIGM, IGH,
SFR, Montpellier, France).20,21
Sequence Data Analysis
All the obtained sequences were aligned with IMGT
tools for nucleotide analysis of immunoglobulin (IG) V-
(D)-J repertoires, polymorphisms, and IG mutations.21
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In NGS data, the following two parameters have been
analyzed for each V-D-J combination: (1) the number of B-
cell clusters, defined as sets of sequences having the same
unique V-D-J and heavy complementarity-determining re-
gion 3 (VH CDR3) rearrangement (number of clusters), and
(2) the total number of sequences obtained in this V-D-J
combination (number of reads). Clusters composed of more
than 50 reads and showing the same VDJ and CDR3 but vari-
ation in the VH domain were considered subclusters, indicat-
ing intraclonal diversity.
The following additional information was also extracted:
(1) IGHV gene usage and percentage of homology to germline
considering the 2% cutoff to discriminate between mutated
and unmutated immunoglobulin genes; (2) the number of nu-
cleotide mutations associated with amino acid changes
(replacement mutation) and the number of nucleotide muta-
tions not associated with amino acid changes (silent mutation)
of the rearranged immunoglobulin genes22-24; and (3) the
amino acid changes, classified as very similar (þþþ), similar
(þþ –,þ –þ), dissimilar (–þ, –þ –,þ –), and very dissimi-
lar (– – –) according to hydropathy, volume, and IMGT physi-
cochemical classes (http:/www.imgt.org/IMGT_vquest/
vquest?livret¼0&Option¼humanIg).21,25 These amino acid
changes are useful to understand affinity maturation mechan-
isms, which result in extensive alteration of the structural pro-
tein conformation that is important in determining the binding
to the antigens.
All “nonubiquitous” sequence changes from the germ-
line were evaluated and further characterized as follows: (1)
unconfirmed mutation (a mutation observed in only one
subclusterd sequence from the same specimen [“unique”])
and (2) confirmed mutation (a mutation observed more than
once among subcluster sequences from the same specimen
[“partially shared”]). Where a clonal expansion was
identified, the sequences that were more mutated were
chosen as representative of the cluster to examine the char-
acteristics of the mutations.
Statistical Analysis
Descriptive statistics for discrete parameters included
counts and frequency distributions. The significance of the
bivariate relationship was assessed by the Fisher exact test.
For all comparisons, a significance level of P at .05 was
set, and all statistical analyses were performed using
GraphPad InStat version 3.05 (GraphPad Software, San
Diego, CA).
Results
TCF3 and ID3 Are Mutated in eBL
ID3 and TCF3 single-nucleotide variants (SNVs) were
found in few eBL cases. Specifically, ID3 SNVs were found
in six (23%) of 26 eBL cases, while TCF3 was found in
three (11.5%) of 26 eBL cases. Since one sample (BL23)
was found to carry SNVs in both genes, eight (30.7%) of 26
eBL cases had ID3 and/or TCF3 variants Table 3 . Sanger
resequencing of genomic DNA confirmed ID3 and TCF3
mutations in 30% and 64% of eBL and sBL samples, re-
spectively. In three samples, matched DNA obtained from
peripheral blood was available; therefore, we could assess
the absence of the SNVs, indicating that the recognized
variants corresponded to somatic mutations Figure 1 .
Comparison of Sequencing Data Derived From the NGS
Analysis With Sanger Sequencing
Multiplex FR1 immunoglobulin H PCR products were
generated and subjected to clonality analysis via 454 NGS,
Table 3
ID3 and TCF3 Single-Nucleotide Variants in eBL
Sample ID Position Reference/Variant Chromosome Symbol Amino Acid Change Type of Mutation
eBL23 NM_002167:702 C/G chr1:23885621 ID3 I99M Missense
NM_002167:650 T/C chr1:23885673 ID3 V82A Missense
NM_002167:649 G/A chr1:23885674 ID3 V82I Missense
NM_002167:700 A/C chr1:23885623 ID3 I99L Missense
eBL49 NM_002167:595 C/T chr1:23885728 ID3 L64F Missense
NM_002167:571 C/T chr1:23885752 ID3 P56S Missense
eBL50 NM_002167:616 C/T chr1:23885707 ID3 Q71 Nonsense
NM_002167:592 C/T chr1:23885731 ID3 Q63 Nonsense
eBL22 NM_002167:595 C/T chr1:23885728 ID3 L64F Missense
eBL69 NM_002167:430 G/A chr1:23885893 ID3 G9S Missense
eBL80 NM_002167:515 C/T chr1:23885808 ID3 P37L Missense
eBL19 NM_001136139:1692 T/A chr19:1612366 TCF3 N551K Missense
eBL20 NM_001136139:1692 T/G chr19:1612366 TCF3 N551K Missense
eBL23 NM_001136139:1709 T/A chr19:1612349 TCF3 V557E Missense
eBL, endemic Burkitt lymphoma.
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followed by data processing, and compared with capillary
electrophoresis.
A total of 130,000 sequences/reads were generated with
an average depth of 3,700 reads, with a minimum depth of
772 reads and a maximum depth of 7,869 reads for each
sample. All 37 cases were clonal on NGS using the criterion
that a clonal cluster(s) must be at least fourfold more abun-
dant than the next largest clonotype of the background.26 In
particular, the presumed monoclonal clusters ranged from
554 to 6,780 reads, representing from 61.8% to 99.7% of the
total reads. On the other hand, the polyclonal background
was composed by high percentages of single reads, ranging
from 0.01% to 2.04% of the total reads.
When all the sequences were aligned with IMGT tools
for nucleotide analysis of immunoglobulin (IG), polymorph-
isms, and IG mutations,21,24 clusters showing identical
IGHV, IGHD, and IGHJ usage and CDR3 regions as the
presumed monoclonal clusters were detected, ranging from
63 to 470 reads, with a range from 8.6% to 35.5% of the
total reads.
Distinct clusters showed specific mutational profiles.
They exhibited shared as well unique somatic mutations and
sequences with different lengths for the presence of
nucleotide deletion. This finding is indicative of intraclonal
diversity and points to the emergence from a common an-
cestor. This phenomenon was particularly evident in all eBL
cases, while only one case of sBL showed different subclus-
ters without differences in length but only differences in
point mutations Table 4 and Figure 2 .
Figure 3 illustrates an example of the branching
of the lymphoma clone (case eBL31) and shows that distinct
subclones evolved along similar, although separate path-
ways, suggesting a selective pressure occurring in parallel
in distinct subclones, thereby improving their BCR
affinities.
To confirm that the presumed monoclonal clusters de-
tected by NGS represented the major tumor cell population,
we carried out Sanger sequencing of PCR products in 37 BL
cases (26 eBL and 11 sBL samples) and analyzed the re-
sults. The VDJ identity of the presumed monoclonal cluster
detected by NGS always corresponded to that inferred with
Sanger direct sequencing.
In addition, we performed cloning of the PCR products
and sequenced at least 20 clones per case. With this
method, we were able to identify at least 69 different
clones with the same VDJ and CDR3 region out of 150
detected by NGS (Table 4). This result can obviously be
explained by the much larger amount of sequence data
generated by NGS. In fact, cloning of the PCR products
confirmed only the clones composed by the highest
number of reads in NGS.
Targeting of Somatic Hypermutation
All eBL cases carried IGHV genes of highly mutated sta-
tus with a germline identity ranging from 79.81% to 97.26%
(median, 90.54%); in sBL cases, the mutational variation com-
pared with the germline ranged from 90.88% to 97.42% (me-
dian, 94.6%). The eBL specimens demonstrated the presence
of somatic mutations in the range of five to 42 mutations. In
contrast, in sBL, the range of mutations was from three to 19
(Table 4). Evaluation of the range of somatic mutations dis-
closed a significant difference between the two subgroups
(eBL and sBL) (P< .0001).
Total mutations in eBL cases were 583 (mean, 22
mutations per case), with a significant prevalence of
replacement mutations (417/583), which were more than
twice that of the silent mutations (166/583) (P < .0001).
The total number of mutations in sBL was 100 (mean,
nine mutations/case), with a slight prevalence of replace-
ment mutations (82/100) over silent mutations (18/100)
(Table 4).
In most of the eBL cases, the majority of mutations
occurred in FRs rather than CDRs, leading to a complemen-
tary-determining region (CDR)/FR ratio greater than 0.3,
200 210 220 230
200 210 220 230
200
80 90 100 110 120
210 220 230 240
210
60 70 80 90
220 230 240
A
B
C
Figure 1 ID3 and/or TCF3 mutations in endemic Burkitt
lymphoma (eBL) and sporadic Burkitt lymphoma (sBL). The
number and percentage of eBL and sBL cases with ID3 and/
or TCF3 mutations are as follows: eight (30%) of 18 for eBL
and eight (64%) of 11 for sBL. Example of biallelic mutation
in the TCF3 (A) and ID3 (B) genes identified in sBL by Sanger
sequencing. C, TCF3 and ID3 wild-type sequences (top row
and bottom row, respectively).
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which would indicate antigen selection. In addition, signifi-
cant accumulation of replacement as opposed to silent muta-
tions was found in the CDRs, which form the antigen
binding sites.27
Our results showed that replacement mutations most
often determine substitutions of amino acids with dissimi-
lar/very dissimilar physicochemical properties rather than
similar/very similar properties, according to the standar-
dized IMGT amino acid classes (Table 4).20,25 Based on
these results, it could be suggested that somatic hypermuta-
tion in BL induces conformational changes that allow the
spatial structure of the antigen binding site to better contact
antigens, thus improving affinity.28
The pattern of amino acid substitutions was similar in
both eBL and sBL, but in sBL, the low number of
replacement mutations does not allow any significant
conclusion.
Analysis of IghV Gene Usage and CDR3 Features
Clonal and in-frame VH gene sequences from BL cases
derived from VH1, VH3, and VH4 families. In particular, in
eBL, the comparison between the clonal VH sequences and
the known germline revealed that 12 (46%) of 26 sequences
were most homologous to the VH3 family (VH3-7, VH3-9,
VH3-11, VH3-15, VH3-23, VH3-30, VH3-72, VH3-74) and,
to a lesser extent, to the VH1 family (10/26, 38%) (VH1-2,
VH1-3, VH1-8, VH1-69). The remaining four were most
closely related to the VH4 family (VH4-34). In sBL, the
usage of the three families was similar to that found in eBL
Table 4
NGS and Sanger Sequencing Analysis of IgV Genes in Burkitt Lymphoma
Case No. VH Usage
No. of Clusters
Range, Mean (%) R/S VD-D/VS-S In/Out Frame
Intraclonal
HeterogeneityNGS Sanger
eBL48 1-2*04 6 2 17-20 (90.58-92.24) 12/7 9/3 6/0 Yes
eBL43 1-3*01 4 1 28-35 (87.85-90.27) 27/8 23/4 4/0 Yes
eBL78 1-69*06 4 2 9-12 (95.83-96-87) 6/6 5/1 4/0 Yes
eBL15 1-69*05 6 3 15-19 (91.67-92.87) 7/12 1/6 4/0 Yes
eBL32 1-69*04 5 2 18-19 (93.15-93.61) 13/6 10/3 5/0 Yes
eBL35 1-69*10 4 1 23-28 (85.21-87.95) 21/7 11/10 4/0 Yes
eBL36 1-69*06 6 2 5-6 (97.26-97.76) 4/2 4/0 6/0 Yes
eBL84 1-69*04 5 3 39-42 (79.81-81.28) 30/10 21/9 5/0 Yes
eBL52 1-69*06 7 3 20-27 (90.62-93.05) 21/6 14/7 3/0 Yes
eBL22 1-8*02 4 1 20-24 (91.67-92.53) 14/10 12/2 4/0 Yes
eBL49 3-7*01 5 2 15-21 (92.71-94.79) 14/7 12/2 5/0 Yes
eBL34 3-9*01 3 1 24-29 (87.34-89.24) 19/10 9/9 5/0 Yes
eBL51 3-11*01 3 1 12-15 (93.27-94.61) 13/2 8/4 3/0 Yes
eBL23 3-15*01 8 5 22-33 (86.66-93.33) 17/6 9/5 5/0 Yes
eBL19 3-23*01 10 4 5-13 (95.20-95.65) 11/2 10/1 3/0 Yes
eBL40 3-23*01 5 2 32-39 (86.48-88.88) 26/13 18/8 5/0 Yes
eBL63 3-23*01 3 2 14-16 (93.57-94.37) 14/1 12/2 3/0 Yes
eBL80 3-23*01 4 1 11-13 (93.98-95.58) 9/4 8/1 4/0 Yes
eBL74 3-23*01 4 1 19-20 (93.06-93.40) 18/2 8/10 4/0 Yes
eBL28 3-30*03 7 3 17-26 (89.60-93.15) 20/6 10/8 7/0 Yes
eBL50 3-72*01 4 2 10-13 (91.37-92.80) 10/3 9/1 4/0 Yes
eBL69 3-74*01 4 2 18-26 (90.97-93.75) 17/9 8/10 4/0 Yes
eBL31 4-34*01 9 5 5-14 (84.15-94.79) 9/5 5/3 5/0 Yes
eBL21 4-34*01 7 3 14-15 (93.18-93.64) 10/5 6/3 5/0 Yes
eBL57 4-34*01 4 1 38-42 (80.91-82.72) 35/7 28/7 3/0 Yes
eBL62 4-34*01 5 2 26-30 (87.76-89.43) 20/10 14/6 2/1 Yes
sBL4169 1-3*01 2 1 8-9 (95.43-95.89) 9/1 5/0 3/0 Yes
sBLE9 3-7*01 1 1 8 (94.84) 8/0 4/4 1/0 No
sBL4452 3-13*01 1 1 7 (96.82) 5/2 3/1 1/0 No
sBLE4 3-21*01 1 1 8 (94.94) 6/2 3/3 2/0 No
sBL4324 3-23*01 1 1 4 (98.21) 4/1 2/1 1/0 No
sBLE2 3-23*01 1 1 11 (93.04) 9/1 7/2 1/0 No
sBLE3 3-23*01 1 1 9 (94.23) 8/1 6/2 1/0 No
sBLE5 3-23*01 1 1 3 (98.10) 4/0 2/1 1/0 No
sBL2552 3-74*01 2 1 18-19 (90.88-91.93) 16/5 12/5 2/0 Yes
sBL8274 4-39*01 2 2 13-16 (93.81-94.25) 9/5 3/5 2/0 Yes
sBLE8 4-39*01 1 1 4 (97.42) 4/0 3/1 1/0 No
eBL, endemic Burkitt lymphoma; NGS, next-generation sequencing; R/S, total replacement to silent mutation ratio; sBL, sporadic Burkitt lymphoma;
VD-D, very dissimilar/dissimilar: (– – –) o (þ – –) o (– þ –) o (– – þ); VS-S, very similar/similar: (þþ þ) o (þþ –) o (–þþ) o (þ – þ).
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(VH1 was found in one of 11 cases, VH3 in eight of 11 cases,
and VH4 in two of 11 cases).
These results enabled us to test whether the cells from
BL were derived randomly from the V gene repertoire ex-
pressed in normal peripheral blood lymphocytes or whether
they exhibited a biased V gene usage. To this end, we com-
pared the VH gene usage of this B-cell population with the re-
arrangements of normal peripheral B lymphocytes (PBLs).29
Our results showed that in BL cases, the VH1,VH3, and VH4
family genes were significantly overrepresented compared with
PBLs (P < .05). In addition, when we looked at the individual
genes, we found a preferential expression of VH3-23 (9/37,
24%), the more represented region in memory B cells, and
VH1-69 (6/37, 16%) and VH4-34 (6/37, 16%). This IGHV rep-
ertoire usage is remarkably biased in comparison to the IGHV
repertoire of normal B cells, where VH3-23, VH1-69, and
VH4-34 are used by 12.1%, 1.4%, and 3.9%, respectively
(IGHV repertoire in eBL and sBL, respectively) Figure 4 .29
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Figure 2 Comparison of next-generation sequencing (NGS) analysis and GeneScan analysis in endemic Burkitt lymphoma
(eBL) and sporadic Burkitt lymphoma (sBL). In NGS analysis for eBL (A) and sBL (B) and GeneScan analysis for eBL (C)
and sBL (D), NGS showed the presence of multiple clusters sharing the same VDJ and CDR3 in eBL compared with sBL. E
and F, sequences of clusters.
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CDR3 from all cases was analyzed both at the nucleo-
tide and amino acid levels. No identical or similar sequences
were identified when comparing the sequences from one
case with those of any other case.
The average VH CDR3 length of BL cells was similar
to that of germinal center and marginal zone B cells (amino
acid, 14.16 vs 14.75 and 15.01, respectively).
We determined the IGHD and IGHJ genes used by the
IGHV-D-J sequences analyzed. The IGHD genes used were
IGHD3 (48%) and IGHD2 (16%) and several others to a
much lower extent, including IGHD1, IGHD4, IGHD5, and
IGHD6. In particular, we demonstrated a bias toward
IGHD3-10 (25%), which was considered statistically sig-
nificant compared with the PBLs (P < .05).29,30 The IGHJ
gene usage in all cases showed that IGHJ4 (56%) was used
the most, followed by IGHJ3 (16%), IGHJ6 (16%), IGHJ5
(8%), and IGHJ1 and IGHJ2 (4%). In sBL, no significant
difference in the distribution between the D and J segment
usage has been found.
Discussion
The World Health Organization classification of BL de-
scribes three clinical variants: endemic, sporadic, and im-
munodeficiency related. These types are similar in
morphology, immunophenotype, and genetic features. The
endemic variant is associated with malaria, and Epstein-
Barr virus (EBV) is found in almost all cases. The sporadic
type occurs mainly throughout the rest of the world (pre-
dominantly North America and Europe) and is less fre-
quently associated with EBV infection.13
It has been questioned whether the different BL subtypes,
being characterized by peculiar epidemiologic and clinical fea-
tures, may also differ in cellular biology and pathogenetic
mechanisms. Interestingly, GEP studies have demonstrated that
eBL and human immunodeficiency virus–BL had almost an
identical molecular profile, whereas sBL cases were relatively
more different.14 Differences between eBL and sBL in signifi-
cant pathways such as BCR, tumor necrosis factor/nuclear
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Figure 3 Evolutionary history of endemic Burkitt lymphoma (eBL) and example of clonal heterogeneity in case eBL31. In case
eBL31, different clusters showing identical IGHV, IGHD, and IGHJ usage and related CDR3 regions but exhibiting different
somatic mutations and sequences with different lengths for the presence of nucleotide deletion were detected by next-gener-
ation sequencing analysis. The putative progenitors are depicted with gray nuclei, and the IGHV gene rearrangement of the clo-
nally related cells deriving from each progenitor is indicated above. Shared point mutations and acquired unique mutations are
indicated above and below the line, respectively. Vertical bars depict S mutations, lollipops depict R mutations, and red squares
depict nucleotide deletions.
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factor jB, and interleukin-dependent intracellular cascades
seem to reflect the different clinical contexts.12
Intriguingly, recent studies using NGS disclosed the
importance of the BCR pathway in the pathogenesis of BL.
In fact, mutations affecting the transcription factor TCF3 or
its negative regulator ID3 were reported in around 70% of
sporadic BL cases. This results in the activation of a tonic
form of BCR signaling and increased expression of genes
belonging to the BCR pathway.9-11
However, it should be considered that the tonic form of
BCR is antigen independent and seems to be in contrast with
the epidemiologic context of chronic antigen stimulation in
which eBL arises.
Since no definitive data are available on the mutations of
TCF3 and ID3 for eBL, the present study was aimed to assess
the frequency of these mutations in eBL and to make a com-
parison with sBL. Overall, eight (30.7%) of 26 eBL cases pre-
sented nonsense or missense mutations, six of 26 in ID3, three
of 26 in TCF3, and one in both genes. Of note, this rate of mu-
tation was significantly lower than that found in our sBL cases
(P ¼ .0300) and those previously reported.9-11 Therefore, our
results seem to suggest that the intrinsic activation of BCR,
due to mutation of TCF3/ID3, is not the more relevant patho-
genetic mechanism in eBL. However, as the genetic landscape
of eBL has not yet extensively studied, it is conceivable that
many more genes belonging to the Wnt/b-catenin/TCF3/ID3
pathway may be also involved in eBL pathogenesis.
To answer whether an activation of BCR through extrin-
sic antigen-driven signaling, due to the presence of multiple
pathogens,31 could be present in eBL, we analyzed SHM sta-
tus of BCR by NGS of immunoglobulin genes. NGS analysis
revealed intraclonal diversity, suggesting an active targeted
SHM process in eBL compared with sBL. In fact, NGS ana-
lysis showed the presence of multiple clusters sharing the
same VDJ and CDR3 in eBL. All these clusters carried also
shared unique somatic mutations in eBL, indicating that these
distinct subclones had expanded under the selective pressure
of antigens, thereby fine-tuning their BCR affinities.
The probability of excess or scarcity of replacement
mutations in CDR and FR regions, calculated by a multi-
modal distribution model, showed signs of antigen selection
mostly in eBL.27 Remarkably, in all cases, we found that re-
placement mutations most often determine substitutions of
amino acids with dissimilar/very dissimilar physicochemi-
cal properties rather than similar/very similar, suggesting an
important remodeling of immunoglobulin structure that
may increase affinity under antigenic pressure.28,32
In addition, most of the VH clusters did not have any
mutations, deletions, or insertions that would prevent or limit
translation. These findings led to the suggestion that mainten-
ance of immunoglobulin expression and dependency on BCR
may also extend to malignant cells. It is tempting to speculate
that the maintenance of immunoglobulin expression and im-
munoglobulin-mediated clonal selection may have a similar
bias since our IGHV gene usage analysis showed that BL
cases have a preferential usage of the VH3-23, VH4-34, and
VH1-69 genes. In this context, it is worthy of note that the
VH4-34 gene encodes for the intrinsically autoreactive anti-
body, suggesting that autoreactive antigens could also be
involved in BL pathogenesis. In addition, during acute EBV
and cytomegalovirus infections, increased titers of IGHV4-
34 antibodies are detected, and patients with CLL infected
with EBV also have IGHV4-34 gene overrepresentation.33-35
However, important unanswered questions still remain con-
cerning whether the VH gene repertoires of individuals living
in endemic areas are skewed compared with those of individ-
uals living in nonendemic areas and whether the African VH
gene repertoires resemble non-African VH gene repertoires.
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Figure 4 IGHV gene usage analysis in endemic Burkitt lymphoma (eBL) (A) and sporadic Burkitt lymphoma (sBL) (B). IGHV
gene usage analysis showed that eBL has a preferential usage of the VH3-23, VH4-34, and VH1-69 family gene and that sBL
has a preferential usage of the VH3-23 family gene.
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In conclusion, our data suggest a strong antigenic pres-
sure that could potentially be related to prolonged micro-
environment interactions, by which chronic stimulation of
BCR with certain pathogens could be important in promot-
ing clonal expansion of B cells expressing distinctive BCRs
and growth of the neoplastic clone. For eBL, this can be
related to the fact that chronic Plasmodium falciparum
malaria stimulation continues to reactivate latently EBV-
infected memory B cells.34-37 Yet, whether coincidental
infections with additional pathogens may occur in eBL
remains to be addressed. On the other hand, in sBL, the
progressive acquisition of mutations in the TCF3/ID3 genes
results in intrinsic tonic activation of BCR signaling.38
Therefore, neoplastic cells may grow in a way that is inde-
pendent of EBV and/or other antigens.39,40 However, we
cannot exclude a combining of tonic and extrinsic BCR sig-
naling activation in a subset of BL.
Our conclusions are also supported by an elegant ex-
perimental model in which stimulation of B cells by antigen
in the presence of overexpressed Myc in engineered mice
gave rise to BL-like tumors that were in turn dependent on
both Myc and the antigen for survival and proliferation.1
Interestingly, the growth of these murine BL could be in-
hibited by treatment with immunosuppressants (cyclo-
phosphamide and cyclosporine). Intriguingly, complete
remission has been achieved in patients with stage 1 to 2 BL
only with cyclophosphamide treatment.41
Deciphering the pathway of BCR activation in BL may
be useful to identify new therapeutic approaches since cases
strongly dependent on extrinsic antigenic signaling appear
to be sensitive to pathway inhibitors targeting PI3K and
BTK, while cases that depend on tonic signaling are not sen-
sitive to BTK inhibitors.42 Successful strategies to eliminate
tumors will need to identify and target multiple oncogenic
pathways operating in the tumor, creating a genetic bottle-
neck too narrow for the tumor’s evolutionary escape.
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